ArticleThe Lancet. Rheumatology2020

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.

Alexander P J Vlaar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.